TL;DR: Aetna, a CVS Health company, modified CPB 0606 governing autologous hematopoietic cell transplantation for autoimmune diseases, effective September 26, 2025. Here's what billing teams need to do.

This update to the Aetna hematopoietic cell transplantation coverage policy tightens the medical necessity criteria for adults with rapidly progressive scleroderma. The change directly affects CPT codes 38206 and 38241 — the autologous harvesting and transplantation codes — along with the broader code set under CPB 0606 in the Aetna system. If your practice or facility bills stem cell transplants for autoimmune indications, this update changes what you need to document before submitting a claim.


Quick-Reference Table

Field Detail
Payer Aetna, a CVS Health company
Policy Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications
Policy Code CPB 0606
Change Type Modified
Effective Date September 26, 2025
Impact Level High
Specialties Affected Hematology/Oncology, Rheumatology, Pulmonology, Transplant Centers
Key Action Audit documentation for FVC, DLCO, creatinine clearance, and LVEF values before submitting CPT 38241 for scleroderma patients

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

CPB 0606 in the Aetna system now specifies exactly what clinical thresholds a patient must meet before autologous hematopoietic cell transplantation (HCT) qualifies as medically necessary for scleroderma. This is not a blanket approval for systemic sclerosis. The patient must meet specific pulmonary or renal criteria — and must clear a separate set of exclusion criteria — before the coverage policy applies.

Here's the core medical necessity gate. The patient must be an adult aged 18 to 69 with rapidly progressive scleroderma at risk of organ failure. Then they must meet one of two entry criteria:

#Covered Indication
1Active interstitial lung disease confirmed by broncho-alveolar cell composition or ground-glass opacities on chest CT, plus either an FVC or DLCO below 70% of predicted value; or
2Previous scleroderma-related renal disease

Meeting one of those two gets the patient into the coverage window. But they also need to clear the exclusion criteria — either by meeting the transplanting institution's selection criteria, or by having none of the following:

#Covered Indication
1Creatinine clearance below 40 ml/min
2DLCO below 40% of predicted value, or FVC below 45% of predicted value
3Pulmonary arterial hypertension
+ 1 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

The real issue here is the dual-gate structure. A patient can qualify on the lung disease criterion, then get disqualified because their DLCO has deteriorated further below 40%. Your clinical team and transplant coordinators need to check both gates — entry and exclusion — before submitting for prior authorization.

For billing, prior authorization is almost certainly required for CPT 38241 (autologous transplantation) and CPT 38206 (autologous blood-derived HPC harvesting) under this policy. Aetna's coverage policy for transplant procedures routinely requires prior auth. Confirm this with your Aetna provider agreement before the transplant workup begins — not after.

Reimbursement for the full transplant episode depends on clean documentation at each step. That means radiology reports confirming ground-glass opacities, pulmonary function tests with FVC and DLCO values expressed as percent of predicted, creatinine clearance labs, and an echocardiogram showing LVEF of 50% or higher. Missing any one of these is a direct path to claim denial.


Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

The HCPCS codes S2140, S2142, and S2150 are explicitly not covered for the indications listed in CPB 0606. These cover cord blood harvesting (S2140), cord blood-derived stem-cell transplantation (S2142), and general bone marrow or blood-derived stem cell harvest/transplant services (S2150).

If your facility bills cord blood transplant services under any of the autoimmune indications covered by CPB 0606, expect denial. These procedures fall outside Aetna's coverage policy for this indication set regardless of clinical rationale. The policy draws a hard line between autologous transplantation using the patient's own cells and cord blood or allogeneic approaches.

Do not attempt to substitute these HCPCS codes for the covered CPT codes. They are structurally different procedures, and Aetna has broken them out separately for a reason.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Rapidly progressive scleroderma (systemic sclerosis) with active interstitial lung disease + FVC or DLCO <70% Covered (when exclusion criteria not met) CPT 38206, 38241; ICD-10 varies Must confirm ground-glass opacities or BAL findings on chest CT; prior auth required
Rapidly progressive scleroderma with prior scleroderma-related renal disease Covered (when exclusion criteria not met) CPT 38206, 38241 Renal disease must be scleroderma-related; document clinical history clearly
Any indication with creatinine clearance <40 ml/min Not covered / excluded Absolute exclusion; no exceptions noted
+ 4 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2025-09-26). Verify your claims match the updated criteria above.

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025

The effective date of September 26, 2025 is already in effect. If you're scheduling transplants now for patients with scleroderma, these criteria apply today.

#Action Item
1

Audit your pre-authorization packets for all pending scleroderma HCT cases. Confirm that each packet includes chest CT reports with ground-glass opacity findings or BAL results, PFTs with FVC and DLCO as percent of predicted, creatinine clearance, and an echocardiogram with LVEF. Any packet missing these values will fail the medical necessity review.

2

Flag the dual-gate structure in your prior auth workflow. Build a checklist that separates the entry criteria from the exclusion criteria. A patient can pass the first gate and fail the second. Your prior auth team needs to check both before submitting.

3

Remove HCPCS codes S2140, S2142, and S2150 from any charge capture templates tied to autoimmune HCT indications. These are not covered under CPB 0606. Using them will generate a claim denial that's hard to appeal given the explicit policy language.

+ 4 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0606

Covered CPT Codes (When Selection Criteria Are Met)

Code Type Description
38204 CPT Management of recipient hematopoietic progenitor cell donor search and cell acquisition
38205 CPT Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206 CPT Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
+ 21 more codes

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Not Covered HCPCS Codes

Code Type Description Reason
S2140 HCPCS Cord blood harvesting for transplantation, allogeneic Not covered for indications listed in CPB 0606
S2142 HCPCS Cord blood-derived stem-cell transplantation, allogeneic Not covered for indications listed in CPB 0606
S2150 HCPCS Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvest and transplantation Not covered for indications listed in CPB 0606

Key ICD-10-CM Diagnosis Codes

The full ICD-10-CM list under CPB 0606 runs to 221 codes. Below are the codes explicitly present in the policy data. Your billing team should cross-reference the full policy at the source before coding edge cases.

Code Description
D45 Polycythemia vera
D46.9 Myelodysplastic syndrome, unspecified (Behcet's disease with myelodysplastic syndrome)
D47.3 Essential (hemorrhagic) thrombocythemia
+ 17 more codes

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

The full ICD-10-CM list includes 221 codes spanning autoimmune, neurological, metabolic, hematologic, and developmental conditions. Pull the complete list from the Aetna CPB 0606 source document before mapping diagnosis codes to claims. Coding to an ICD-10 that doesn't appear on the covered list is a fast path to claim denial with limited appeal options.


Get the Full Picture for CPT 38241

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee